What is the Richmond Agitation‑Sedation Scale (RASS) and what target range should be aimed for in ICU patients not receiving neuromuscular blockade?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Richmond Agitation-Sedation Scale (RASS)

The Richmond Agitation-Sedation Scale (RASS) is a validated 10-point scale ranging from +4 (combative) to -5 (unarousable) used to assess sedation and agitation levels in ICU patients, with a target range of RASS -2 to 0 (light sedation to awake and calm) recommended for mechanically ventilated patients not receiving neuromuscular blockade. 1

Scale Structure and Definitions

The RASS provides clearly defined levels across the sedation-agitation spectrum 1:

Agitation levels:

  • +4: Combative, overtly combative or violent
  • +3: Very agitated, pulls or removes tubes/catheters, aggressive
  • +2: Agitated, frequent non-purposeful movement
  • +1: Restless, anxious but movements not aggressive or vigorous 1

Calm state:

  • 0: Alert and calm 1

Sedation levels:

  • -1: Drowsy, not fully alert but sustained awakening to voice (eye opening/contact >10 seconds)
  • -2: Light sedation, briefly awakens to voice with eye contact (<10 seconds)
  • -3: Moderate sedation, movement or eye opening to voice but no eye contact
  • -4: Deep sedation, no response to voice but movement or eye opening to physical stimulation
  • -5: Unarousable, no response to voice or physical stimulation 1

Target Sedation Range

For ICU patients not receiving neuromuscular blockade, maintain RASS between -2 and 0, which corresponds to light sedation through awake and calm states 1. This target range allows patients to purposefully follow commands without agitation 1.

Clinical Management Based on RASS Score

If under-sedated (RASS >0, SAS >4):

  • First assess and treat pain adequately
  • Use non-benzodiazepine sedatives preferentially (unless alcohol or benzodiazepine withdrawal suspected)
  • Administer sedatives as needed to achieve target 1

If over-sedated (RASS <-2, SAS <3):

  • Hold sedatives immediately until patient reaches target range
  • Restart sedation at 50% of previous dose
  • Avoid non-therapeutic coma unless clinically indicated 1

Validation and Reliability

The RASS demonstrates excellent psychometric properties 1:

  • Inter-rater reliability: Weighted kappa of 0.91 among diverse ICU clinicians (physicians, nurses, pharmacists) 2
  • Validity: Strong correlation (r = 0.93) with visual analog scales and other validated measures 2
  • Longitudinal reliability: Validated for detecting changes in sedation status over consecutive days of ICU care 3
  • Broad applicability: Reliable across medical, surgical, cardiac surgery, coronary, and neuroscience ICUs, in both mechanically ventilated and non-ventilated patients 2

Assessment Frequency and Implementation

Assess sedation using RASS at least 4 times per shift and as needed 1. The scale is preferred over vital signs alone for sedation assessment, as vital signs should only serve as a cue for further evaluation 1.

Key Implementation Points

  • RASS is one of two preferred sedation assessment tools (along with SAS) based on superior validation evidence 1
  • The scale is described by ICU nurses as logical, easy to administer, and readily recalled 2
  • For patients receiving neuromuscular blockade, brain function monitoring should supplement sedation assessment 1
  • RASS assessment should be integrated into sedation protocols and daily checklists for pain, agitation, and delirium management 1

Clinical Outcomes Associated with Target Range

Maintaining lighter sedation levels (RASS -2 to 0) is associated with improved clinical outcomes 1:

  • Shorter duration of mechanical ventilation 1
  • Reduced ICU length of stay 1
  • Lower incidence and duration of delirium 1
  • Facilitation of early mobilization and spontaneous breathing trials 4

Common Pitfalls to Avoid

  • Do not use deep sedation (RASS <-2) routinely unless specifically indicated by clinical circumstances such as elevated intracranial pressure, severe ARDS requiring paralysis, or refractory status epilepticus 1, 4
  • Avoid using brief daily sedation interruption as justification for deep sedation during the remainder of the day when not clinically indicated 4
  • Always treat pain first before escalating sedation, as untreated pain is a common cause of apparent agitation 1
  • Preferentially use non-benzodiazepine sedatives (propofol or dexmedetomidine) rather than benzodiazepines, as benzodiazepine use is a strong independent risk factor for delirium 1, 5

References

2
Research

The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients.

American journal of respiratory and critical care medicine, 2002

Related Questions

A 68-year-old white male, 21 days post total hip arthroplasty, has itching at the clean, dry surgical site without drainage; what measures can be taken to resolve or minimize the itching?
In a 79-year-old patient receiving enteral tube feeding who presents with diarrhea, which stool test should be ordered first?
In a 55‑year‑old man with a recent electrocardiogram showing sinus rhythm, a QS complex in V1, poor R‑wave progression in V2, left‑atrial enlargement, and a prolonged QT interval, what is the most likely diagnosis and appropriate treatment?
How do I convert an infusion rate of 60 cc per hour to drops per minute using a microdrip set?
What is the appropriate evaluation and management for an 82‑year‑old male presenting with lower abdominal pain and a burning sensation on urination?
In a patient with a mild anterior talofibular ligament (ATFL) sprain and several months of persistent pain, is a steroid injection appropriate?
What evidence supports using a one‑way (anti‑reflux) valve on Foley and suprapubic catheters to reduce catheter‑associated urinary tract infections?
Is Bromfed DM (brompheniramine, pseudoephedrine, dextromethorphan) safe for a patient with a bicuspid aortic valve?
What are the recommended diagnostic confirmation and management strategies for a patient with Fragile‑X syndrome?
What is the definition of alcoholic ketoacidosis?
What are the differences between a skin graft and a flap in reconstructive surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.